Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanno Hock

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Leukemia|July 18, 2020
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapyVinayak Venkataraman, Keagan S Casey, Maristela Onozato, et al.
Frontiers in Cell and Developmental Biology|August 2, 2021
The Second Oncogenic Hit Determines the Cell Fate of <i>ETV6-RUNX1</i> Positive LeukemiaGuillermo Rodríguez-Hernández, Ana Casado-García, Marta Isidro-Hernández, et al.
Nature Communications|January 24, 2026
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regenerationNikolaos Tsopoulidis, Masaki Yagi, Justin Brumbaugh, et al.
Leukemia & Lymphoma|January 25, 2022
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adultsPhilip Amrein, Karen Ballen, Kristen Stevenson, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Leukemia|July 18, 2020
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapyVinayak Venkataraman, Keagan S Casey, Maristela Onozato, et al.
Frontiers in Cell and Developmental Biology|August 2, 2021
The Second Oncogenic Hit Determines the Cell Fate of <i>ETV6-RUNX1</i> Positive LeukemiaGuillermo Rodríguez-Hernández, Ana Casado-García, Marta Isidro-Hernández, et al.
Nature Communications|January 24, 2026
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regenerationNikolaos Tsopoulidis, Masaki Yagi, Justin Brumbaugh, et al.
Leukemia & Lymphoma|January 25, 2022
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adultsPhilip Amrein, Karen Ballen, Kristen Stevenson, et al.
Cancer Cell|April 20, 2004
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defectsDavid A Tuveson, Alice T Shaw, Nicholas A Willis, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
British Journal of Haematology|July 13, 2026
Clinical outcomes of combination treatment with FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1/2 (IDH1/2) inhibitors in patients with acute myeloid leukaemiaCatherine Gutierrez Moore, Donian I Chyong, Naval Daver, et al.
Cancer|December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemiaRupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Pageof 4